19
Nov
AbbVie: Boring Business, Beautiful Cash Flow
AbbVie survived the Humira patent cliff everyone feared. Now at single-digit P/E with $22B in free cash flow and a 3% yield, you're paying for pharma discipline while others chase biotech moonshots. Sometimes boring wins.
3 min read